پراسوگرل (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "پراسوگرل" in Persian language version.

refsWebsite

Global rank Persian rank

16nih.gov

4^th place

5^th place

14doi.org

2^nd place

4semanticscholar.org

11^th place

52^nd place

3web.archive.org

1^st place

1europa.eu

68^th place

179^th place

1archive.org

6^th place

9^th place

1nejm.org

2,374^th place

2,531^st place

1fda.gov

447^th place

382^nd place

1lilly.com

low place

1unizar.es

low place

archive.org

Wiviott, Stephen D.; Braunwald, Eugene; McCabe, Carolyn H.; Montalescot, Gilles; Ruzyllo, Witold; Gottlieb, Shmuel; Neumann, Franz-Joseph; Ardissino, Diego; De Servi, Stefano; Murphy, Sabina A.; Riesmeyer, Jeffrey; Weerakkody, Govinda; Gibson, C. Michael; Antman, Elliott M. (15 November 2007). "Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes". New England Journal of Medicine. 357 (20): 2001–2015. doi:10.1056/NEJMoa0706482. PMID 17982182.

doi.org

Baker WL, White CM (2009). "Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes". American Journal of Cardiovascular Drugs. 9 (4): 213–29. doi:10.2165/1131209-000000000-00000. PMID 19655817. S2CID 37160513.
Wiviott, Stephen D.; Braunwald, Eugene; McCabe, Carolyn H.; Montalescot, Gilles; Ruzyllo, Witold; Gottlieb, Shmuel; Neumann, Franz-Joseph; Ardissino, Diego; De Servi, Stefano; Murphy, Sabina A.; Riesmeyer, Jeffrey; Weerakkody, Govinda; Gibson, C. Michael; Antman, Elliott M. (15 November 2007). "Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes". New England Journal of Medicine. 357 (20): 2001–2015. doi:10.1056/NEJMoa0706482. PMID 17982182.
Chew, Derek P; Scott, Ian A; Cullen, Louise; French, John K; Briffa, Tom G; Tideman, Philip A; Woodruffe, Stephen; Kerr, Alistair; Branagan, Maree; Aylward, Philip EG (August 2016). "National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016". Medical Journal of Australia. 205 (3): 128–133. doi:10.5694/mja16.00368. PMID 27465769. S2CID 13014429.
Bellemain-Appaix, A.; Kerneis, M.; O'Connor, S. A.; Silvain, J.; Cucherat, M.; Beygui, F.; Barthelemy, O.; Collet, J.-P.; Jacq, L.; Bernasconi, F.; Montalescot, G. (24 October 2014). "Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis". BMJ. 347 (aug06 2): g6269. doi:10.1136/bmj.g6269. PMC 4208629. PMID 25954988.
Montalescot, Gilles; Bolognese, Leonardo; Dudek, Dariusz; Goldstein, Patrick; Hamm, Christian; Tanguay, Jean-Francois; ten Berg, Jurrien M.; Miller, Debra L.; Costigan, Timothy M.; Goedicke, Jochen; Silvain, Johanne; Angioli, Paolo; Legutko, Jacek; Niethammer, Margit; Motovska, Zuzana; Jakubowski, Joseph A.; Cayla, Guillaume; Visconti, Luigi Oltrona; Vicaut, Eric; Widimsky, Petr (12 September 2013). "Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes". New England Journal of Medicine. 369 (11): 999–1010. doi:10.1056/NEJMoa1308075. PMID 23991622.
John J, Koshy SK (2012). "Current oral antiplatelets: focus update on prasugrel". Journal of the American Board of Family Medicine. 25 (3): 343–9. doi:10.3122/jabfm.2012.03.100270. PMID 22570398.
Demcsák A, Lantos T, Bálint ER, Hartmann P, Vincze Á, Bajor J, et al. (2018-11-19). "PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis". Frontiers in Physiology. 9: 1550. doi:10.3389/fphys.2018.01550. PMC 6252380. PMID 30510515.
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. (September 2009). "Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials". Lancet. 374 (9694): 989–997. doi:10.1016/S0140-6736(09)61525-7. PMID 19726078. S2CID 205956050.
Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, et al. (September 2016). "Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial". The American Journal of Medicine. 129 (9): 1002–5. doi:10.1016/j.amjmed.2016.03.042. PMID 27143321.
Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, et al. (January 2007). "A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation". American Heart Journal. 153 (1): 66.e9–16. doi:10.1016/j.ahj.2006.10.010. PMID 17174640.
Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al. (December 2007). "Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial". Circulation. 116 (25): 2923–32. doi:10.1161/CIRCULATIONAHA.107.740324. PMID 18056526.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. (November 2007). "Prasugrel versus clopidogrel in patients with acute coronary syndromes". The New England Journal of Medicine. 357 (20): 2001–15. doi:10.1056/NEJMoa0706482. PMID 17982182.
Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, et al. (April 2006). "Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450". Drug Metabolism and Disposition. 34 (4): 600–7. doi:10.1124/dmd.105.007989. PMID 16415119. S2CID 1698598.
Kurokawa T, Fukami T, Yoshida T, Nakajima M (March 2016). "Arylacetamide Deacetylase is Responsible for Activation of Prasugrel in Human and Dog". Drug Metabolism and Disposition. 44 (3): 409–16. doi:10.1124/dmd.115.068221. PMID 26718653.

europa.eu

ema.europa.eu

"European Public Assessment Report for Efient" (PDF). EMA. 2009. Archived from the original (PDF) on 19 March 2018. Retrieved 13 March 2021.

fda.gov

"Effient (prasugrel hydrochloride) Prescribing Information". U.S. Food and Drug Administration (FDA). September 2011. Archived from the original on 18 January 2017. Retrieved 13 March 2021.

lilly.com

pi.lilly.com

«Efient: Highlights of prescribing information» (PDF). بایگانی‌شده از اصلی (PDF) در ۱۰ ژوئیه ۲۰۱۹. دریافت‌شده در ۱۳ مارس ۲۰۲۱.

nejm.org

Montalescot, Gilles; Bolognese, Leonardo; Dudek, Dariusz; Goldstein, Patrick; Hamm, Christian; Tanguay, Jean-Francois; ten Berg, Jurrien M.; Miller, Debra L.; Costigan, Timothy M.; Goedicke, Jochen; Silvain, Johanne; Angioli, Paolo; Legutko, Jacek; Niethammer, Margit; Motovska, Zuzana; Jakubowski, Joseph A.; Cayla, Guillaume; Visconti, Luigi Oltrona; Vicaut, Eric; Widimsky, Petr (12 September 2013). "Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes". New England Journal of Medicine. 369 (11): 999–1010. doi:10.1056/NEJMoa1308075. PMID 23991622.

nih.gov

pubmed.ncbi.nlm.nih.gov

Baker WL, White CM (2009). "Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes". American Journal of Cardiovascular Drugs. 9 (4): 213–29. doi:10.2165/1131209-000000000-00000. PMID 19655817. S2CID 37160513.
Wiviott, Stephen D.; Braunwald, Eugene; McCabe, Carolyn H.; Montalescot, Gilles; Ruzyllo, Witold; Gottlieb, Shmuel; Neumann, Franz-Joseph; Ardissino, Diego; De Servi, Stefano; Murphy, Sabina A.; Riesmeyer, Jeffrey; Weerakkody, Govinda; Gibson, C. Michael; Antman, Elliott M. (15 November 2007). "Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes". New England Journal of Medicine. 357 (20): 2001–2015. doi:10.1056/NEJMoa0706482. PMID 17982182.
Chew, Derek P; Scott, Ian A; Cullen, Louise; French, John K; Briffa, Tom G; Tideman, Philip A; Woodruffe, Stephen; Kerr, Alistair; Branagan, Maree; Aylward, Philip EG (August 2016). "National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016". Medical Journal of Australia. 205 (3): 128–133. doi:10.5694/mja16.00368. PMID 27465769. S2CID 13014429.
Bellemain-Appaix, A.; Kerneis, M.; O'Connor, S. A.; Silvain, J.; Cucherat, M.; Beygui, F.; Barthelemy, O.; Collet, J.-P.; Jacq, L.; Bernasconi, F.; Montalescot, G. (24 October 2014). "Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis". BMJ. 347 (aug06 2): g6269. doi:10.1136/bmj.g6269. PMC 4208629. PMID 25954988.
Montalescot, Gilles; Bolognese, Leonardo; Dudek, Dariusz; Goldstein, Patrick; Hamm, Christian; Tanguay, Jean-Francois; ten Berg, Jurrien M.; Miller, Debra L.; Costigan, Timothy M.; Goedicke, Jochen; Silvain, Johanne; Angioli, Paolo; Legutko, Jacek; Niethammer, Margit; Motovska, Zuzana; Jakubowski, Joseph A.; Cayla, Guillaume; Visconti, Luigi Oltrona; Vicaut, Eric; Widimsky, Petr (12 September 2013). "Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes". New England Journal of Medicine. 369 (11): 999–1010. doi:10.1056/NEJMoa1308075. PMID 23991622.
John J, Koshy SK (2012). "Current oral antiplatelets: focus update on prasugrel". Journal of the American Board of Family Medicine. 25 (3): 343–9. doi:10.3122/jabfm.2012.03.100270. PMID 22570398.
Demcsák A, Lantos T, Bálint ER, Hartmann P, Vincze Á, Bajor J, et al. (2018-11-19). "PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis". Frontiers in Physiology. 9: 1550. doi:10.3389/fphys.2018.01550. PMC 6252380. PMID 30510515.
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. (September 2009). "Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials". Lancet. 374 (9694): 989–997. doi:10.1016/S0140-6736(09)61525-7. PMID 19726078. S2CID 205956050.
Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, et al. (September 2016). "Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial". The American Journal of Medicine. 129 (9): 1002–5. doi:10.1016/j.amjmed.2016.03.042. PMID 27143321.
Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, et al. (January 2007). "A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation". American Heart Journal. 153 (1): 66.e9–16. doi:10.1016/j.ahj.2006.10.010. PMID 17174640.
Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al. (December 2007). "Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial". Circulation. 116 (25): 2923–32. doi:10.1161/CIRCULATIONAHA.107.740324. PMID 18056526.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. (November 2007). "Prasugrel versus clopidogrel in patients with acute coronary syndromes". The New England Journal of Medicine. 357 (20): 2001–15. doi:10.1056/NEJMoa0706482. PMID 17982182.
Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, et al. (April 2006). "Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450". Drug Metabolism and Disposition. 34 (4): 600–7. doi:10.1124/dmd.105.007989. PMID 16415119. S2CID 1698598.
Kurokawa T, Fukami T, Yoshida T, Nakajima M (March 2016). "Arylacetamide Deacetylase is Responsible for Activation of Prasugrel in Human and Dog". Drug Metabolism and Disposition. 44 (3): 409–16. doi:10.1124/dmd.115.068221. PMID 26718653.

ncbi.nlm.nih.gov

Bellemain-Appaix, A.; Kerneis, M.; O'Connor, S. A.; Silvain, J.; Cucherat, M.; Beygui, F.; Barthelemy, O.; Collet, J.-P.; Jacq, L.; Bernasconi, F.; Montalescot, G. (24 October 2014). "Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis". BMJ. 347 (aug06 2): g6269. doi:10.1136/bmj.g6269. PMC 4208629. PMID 25954988.
Demcsák A, Lantos T, Bálint ER, Hartmann P, Vincze Á, Bajor J, et al. (2018-11-19). "PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis". Frontiers in Physiology. 9: 1550. doi:10.3389/fphys.2018.01550. PMC 6252380. PMID 30510515.

semanticscholar.org

api.semanticscholar.org

Baker WL, White CM (2009). "Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes". American Journal of Cardiovascular Drugs. 9 (4): 213–29. doi:10.2165/1131209-000000000-00000. PMID 19655817. S2CID 37160513.
Chew, Derek P; Scott, Ian A; Cullen, Louise; French, John K; Briffa, Tom G; Tideman, Philip A; Woodruffe, Stephen; Kerr, Alistair; Branagan, Maree; Aylward, Philip EG (August 2016). "National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016". Medical Journal of Australia. 205 (3): 128–133. doi:10.5694/mja16.00368. PMID 27465769. S2CID 13014429.
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. (September 2009). "Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials". Lancet. 374 (9694): 989–997. doi:10.1016/S0140-6736(09)61525-7. PMID 19726078. S2CID 205956050.
Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, et al. (April 2006). "Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450". Drug Metabolism and Disposition. 34 (4): 600–7. doi:10.1124/dmd.105.007989. PMID 16415119. S2CID 1698598.

unizar.es

zaguan.unizar.es

Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, et al. (September 2016). "Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial". The American Journal of Medicine. 129 (9): 1002–5. doi:10.1016/j.amjmed.2016.03.042. PMID 27143321.

web.archive.org

"European Public Assessment Report for Efient" (PDF). EMA. 2009. Archived from the original (PDF) on 19 March 2018. Retrieved 13 March 2021.
"Effient (prasugrel hydrochloride) Prescribing Information". U.S. Food and Drug Administration (FDA). September 2011. Archived from the original on 18 January 2017. Retrieved 13 March 2021.
«Efient: Highlights of prescribing information» (PDF). بایگانی‌شده از اصلی (PDF) در ۱۰ ژوئیه ۲۰۱۹. دریافت‌شده در ۱۳ مارس ۲۰۲۱.